Search the Newsreel

Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreak

Moderna has initiated a Phase 1 clinical trial for an Ebola vaccine, mRNA-1469, targeting the Bundibugyo strain prevalent in the Democratic Republic of the Congo. The trial, conducted in Canada with approximately 80 participants, will assess the vaccine's safety and tolerability using the same …

Moderna starts Phase 1 trial of mRNA Bundibugyo Ebola vaccine

Moderna has initiated a Phase 1 clinical trial for its mRNA-1469 vaccine, targeting the Bundibugyo ebolavirus strain for which no approved vaccine currently exists. The trial, backed by up to $50 million from CEPI, will enroll approximately 80 healthy adults in Canada to assess …

Health Canada approves clinical trial for Moderna’s mRNA Ebola vaccine

Health Canada has approved Moderna to begin a Phase I clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus, which is causing an outbreak in the Democratic Republic of the Congo. Canada is the second country, after the U.K., …

Moderna begins first human trial of Bundibugyo Ebola vaccine

Moderna has initiated its first human trial for an experimental vaccine targeting the Bundibugyo ebolavirus, a strain responsible for over 1,650 deaths and currently lacking an approved vaccine. The mRNA-based vaccine, mRNA-1469, is being tested in Canada on approximately 80 healthy adults to assess …

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Moderna has initiated a Phase 1 clinical trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus (BDBV), a strain of Ebola with no currently licensed vaccines. The trial, conducted in Canada, is part of an expanded collaboration with CEPI, which has committed up to …

Moderna vaccinates first participants in trial for Ebola strain with no vaccine

Moderna has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine, mRNA-1469, designed to prevent Bundibugyo ebolavirus (BDBV) disease, a strain of Ebola for which no licensed vaccines currently exist. The study will assess the safety, tolerability, and immunogenicity of …

Moderna Begins Human Trial of Experimental Ebola Vaccine in Canada

Moderna has initiated human trials in Canada for an experimental Ebola vaccine, which is the second candidate to enter clinical trials for the strain causing the current outbreak in the Democratic Republic of Congo. The vaccine utilizes Moderna's mRNA platform and is being tested …

Modern Mills for Food Products Co. Revenue Breakdown – TADAWUL:2284

Sei Investments Co. Acquires 55,939 Shares of Moderna, Inc. $MRNA

Sei Investments Co. increased its stake in Moderna, Inc. by 76.2% in the first quarter, acquiring 55,939 additional shares to bring its total holdings to 129,395 shares valued at approximately $6.6 million. Despite this institutional buying, company insiders have sold a significant number of …

China Modern Dairy Lifts Stake in China Shengmu to 83.5% as Takeover Offer Closes

Here's Why We're Not Too Worried About Modern Innovative Digital Technology's (HKG:2322) Cash Burn Situation

Moderna, Inc. (MRNA) Stock Analysis: Exploring a 9.75% Potential Downside in the Biotech Leader

Moderna, Inc. (MRNA) is a biotech leader facing a potential 9.75% downside from its current trading price of $54.82, according to analyst targets. Despite its innovative mRNA technology and strategic partnerships, the company has a negative forward P/E ratio and concerning return on equity, …

Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says

RBC analysts indicate that Moderna (MRNA) is expected to encounter multiple challenges in its vaccine sector in the near to medium term. The article, reserved for members, suggests these headwinds could impact the company's performance, despite recent news about narrowed Q2 losses and increased …

China Modern Dairy Lifts Stake in Shengmu to 83.5% After Offer Close

Hamilton Wealth LLC Sells 24,338 Shares of Moderna, Inc. $MRNA

Hamilton Wealth LLC decreased its stake in Moderna, Inc. by 23.2% in the first quarter, selling 24,338 shares. Despite mixed institutional investor activity and a generally cautious analyst outlook with a "Reduce" rating, Moderna's recent quarterly results exceeded revenue and EPS expectations. Insiders have …

Amundi Reduces Holdings in Moderna, Inc. $MRNA

Amundi reduced its stake in Moderna, Inc. by 20.9% in the first quarter, selling 238,790 shares and retaining 904,823 shares valued at approximately $46 million. Despite beating reduced earnings expectations, Moderna continues to face substantial losses, declining COVID-19 vaccine demand, and a setback in …

Militia Capital Management LLC Buys New Shares in Moderna, Inc. $MRNA

Militia Capital Management LLC acquired 23,001 shares of Moderna, Inc. (NASDAQ:MRNA) worth approximately $1.168 million in the first quarter. This comes as various institutional investors have adjusted their stakes in Moderna, and company insiders have sold shares. The article also provides an overview of …

Does Moderna’s Wider 2026 Loss Amid Pipeline Spend Change The Bull Case For MRNA?

Moderna reported a wider net loss of US$2.13 billion in the first half of 2026 due to significant pipeline development spending, despite a slight revenue increase. The company's investment narrative heavily relies on FDA approval for its influenza vaccine, mFLUSIVA, and successful commercialization of …

ETFs Investing in Moderna, Inc. Stocks

This article provides a comprehensive list of ETFs that invest in Moderna, Inc. stocks, detailing market value, weight, issuer, management style, expense ratio, and AUM for each fund. It aims to help investors identify various ETF options for gaining exposure to Moderna, Inc. while …

Moderna, Inc. $MRNA Position Reduced by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Moderna (MRNA) by 29.7% in Q1 2026, selling 132,808 shares and retaining 314,872 shares valued at $16.0 million. Despite Moderna reporting a better-than-expected Q2 loss and improved revenue, the company faces declining COVID-19 vaccine sales, …

Moderna (MRNA) Stock Falls As Pipeline Delays Cloud Revenue Growth

Moderna Stock Falls 5% After Trimming Financial Outlook

Moderna Number of Employees 2026 | Employee Count & Headcount Data

Moderna (NASDAQ: MRNA) had approximately 4,670 total employees worldwide as of March 2026, representing a 16.3% decline since 2023. Despite this reduction in overall headcount, the company is actively hiring, with 219 active job postings in 2026, a 23.5% increase from 2025. The workforce …

Moderna, Inc. 2026: Revenue $145M, Net income ($782M), EPS ($1.97) — 10-Q Summary

Moderna, Inc. reported its 2026 quarterly results, showing revenue of $145 million, a net loss of $782 million, and a diluted loss per share of $1.97. The company experienced slight revenue improvement and narrower losses compared to the prior year. Revenue growth was attributed …

Moderna Says Norovirus Vaccine Didn’t Meet Statistical Criteria for Early Success in Trial

Moderna's stock fell after its norovirus vaccine candidate failed to meet early success criteria in a late-stage trial's interim analysis. The company announced it is still enrolling additional participants for the ongoing, blinded study. This news came as Moderna narrowed its second-quarter loss, with …

Moderna (Nasdaq: MRNA) details Q2 loss and $950 million patent settlement

Moderna (MRNA) reported a Q2 2026 net loss of $782 million, or $(1.97) per share, with revenue of $145 million, roughly flat year-over-year. The company's six-month net loss widened to $2.125 billion due to a significant increase in the cost of sales, primarily driven …

Moderna Inc reports results for the quarter ended June 30 - Earnings Summary

Moderna Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief announcement about these financial results. Readers can access the full report for detailed information.

Moderna maintains 10% growth target despite Phase 3 norovirus miss

Moderna is upholding its target of up to 10% revenue growth for the year, largely due to strong ex-U.S. vaccine sales and the anticipated approval of its seasonal flu vaccine, mFLUSIVA, despite a recent setback in its Phase 3 norovirus vaccine trial. The norovirus …

Moderna Q2 earnings beat estimates as norovirus vaccine stumbles

Moderna reported a narrower net loss in Q2 2026, beating Wall Street estimates, and saw a slight increase in total revenue. However, the company's stock dropped after its norovirus vaccine candidate failed to meet early success criteria in a Phase 3 trial. Moderna improved …

Moderna, Inc., (MRNA) Earnings Preview: Reports Before the Open

Moderna, Inc. (MRNA) is scheduled to report its earnings before the market opens. Investors will be focusing on the sales performance of its RSV vaccine and the data from its personalized mRNA cancer trial to gauge the company's future growth prospects beyond COVID boosters.

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

Moderna (MRNA) reported a Q2 loss of $1.97 per share, matching Zacks Consensus Estimate, and surpassed revenue estimates with $145 million, beating expectations by 14.49%. The company has consistently topped revenue estimates and its shares have significantly outperformed the S&P 500 year-to-date. Despite the …

Moderna Says Early Results of Norovirus Shot Were Not Successful

Moderna announced that early results from a key phase 3 trial for its norovirus vaccine did not meet statistical criteria for early success, marking a setback for the company's diversification efforts. The study is still ongoing, and Moderna plans to recruit more patients to …

Moderna: Q2 Earnings Snapshot

This article is a placeholder for Moderna's Q2 earnings snapshot. It currently contains no detailed information regarding the company's financial performance.

Moderna (NASDAQ: MRNA) Q2 2026 loss, trims 2026 spending

Moderna reported a net loss of $782 million, or $1.97 per share, for Q2 2026, despite revenue slightly exceeding the prior year at $145 million. The company reiterated its target of up to 10% revenue growth for 2026 and improved its financial outlook by …

Moderna beats quarterly revenue estimates on COVID vaccine strength

Moderna exceeded Wall Street's second-quarter revenue estimates due to strong COVID-19 vaccine sales, despite a setback with its experimental norovirus vaccine candidate. The company aims to offset declining pandemic-era vaccine sales with its flu shot and a future COVID-flu combination, reaffirming its revenue growth …

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates

Moderna reported its second-quarter 2026 financial results, with total revenue of $0.1 billion, a GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). The company reiterated its plan for up to 10% revenue growth in 2026, improved its GAAP operating expense outlook …